We performed a systematic review and meta-analysis on the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) derived from pretreatment 18F-FDG PET/CT in patients with esophageal cancer.
PubMed and EMBASE databases were searched until April 12, 2018, for studies that evaluated MTV or TLG as prognostic factors in esophageal cancer, with overall survival (OS) and event-free survival serving as the end points. Hazard ratios (HRs) were meta-analytically pooled using a random-effects model. Subgroup analyses based on the clinicopathological and PET variables were performed.
In total, 16 studies with 1294 patients were included. The pooled HRs of MTV and TLG for OS were 2.26 (95% confidence interval [CI], 1.73–2.96) and 2.23 (95% CI, 1.73–2.87), respectively. Regarding event-free survival, the pooled HRs of MTV and TLG were 2.03 (95% CI, 1.66–2.49) and 2.57 (95% CI, 1.82–3.62), respectively. Metabolic tumor volume was found to be a significant prognostic factor for OS consistently across multiple subgroups classified based on stage, histological subtype, treatment, delineation of volume of interest, and the determination method of cutoff value, with pooled HRs ranging from 1.96 to 2.54.
In patients with esophageal cancer, MTV and TLG derived from pretreatment 18F-FDG PET are significant prognostic factors. As prognostic biomarkers, volumetric metabolic parameters may bolster the role of 18F-FDG PET in the management of esophageal cancer.
From the *Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul;
†Department of Radiation Oncology, Kangwon National University Hospital, Chuncheon
‡Department of Radiology, Seoul National University College of Medicine; and
§Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Received for publication May 25, 2018; revision accepted August 18, 2018.
S.H. and Y.J.K. contributed equally to this work.
Conflicts of interest and sources of funding: none declared.
Correspondence to: Jong Jin Lee, MD, PhD, Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. E-mail: email@example.com.